Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 4.11
NAS:SCYX's Cash-to-Debt is ranked higher than
53% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:SCYX: 4.11 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SCYX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 4.11 Max: No Debt
Current: 4.11
Equity-to-Asset 0.58
NAS:SCYX's Equity-to-Asset is ranked lower than
56% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NAS:SCYX: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SCYX' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.73  Med: 0.58 Max: 0.85
Current: 0.58
-8.73
0.85
Piotroski F-Score: 3
Altman Z-Score: -2.83
Beneish M-Score: -3.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -10866.02
NAS:SCYX's Operating Margin % is ranked lower than
98% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. NAS:SCYX: -10866.02 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SCYX' s Operating Margin % Range Over the Past 10 Years
Min: -10866.02  Med: -46.23 Max: 11030.74
Current: -10866.02
-10866.02
11030.74
Net Margin % -11714.45
NAS:SCYX's Net Margin % is ranked lower than
98% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:SCYX: -11714.45 )
Ranked among companies with meaningful Net Margin % only.
NAS:SCYX' s Net Margin % Range Over the Past 10 Years
Min: -12693.77  Med: -337.1 Max: -68.17
Current: -11714.45
-12693.77
-68.17
ROE % -79.39
NAS:SCYX's ROE % is ranked lower than
90% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. NAS:SCYX: -79.39 )
Ranked among companies with meaningful ROE % only.
NAS:SCYX' s ROE % Range Over the Past 10 Years
Min: -86.56  Med: -82.35 Max: -78.13
Current: -79.39
-86.56
-78.13
ROA % -56.74
NAS:SCYX's ROA % is ranked lower than
90% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. NAS:SCYX: -56.74 )
Ranked among companies with meaningful ROA % only.
NAS:SCYX' s ROA % Range Over the Past 10 Years
Min: -248.61  Med: -73.36 Max: -16.27
Current: -56.74
-248.61
-16.27
GuruFocus has detected 4 Warning Signs with SCYNEXIS Inc $NAS:SCYX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SCYX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:SCYX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:SPHS, NAS:EPIX, NAS:BPTH, OTCPK:MGCLF, NAS:LPCN, NAS:AGRX, NAS:GALT, OTCPK:CPHRF, NAS:TYHT, NAS:STDY, OTCPK:CKPT, NAS:MEIP, NAS:OREX, OTCPK:ZOMHF, OTCPK:MGWFF, NAS:PSDV, NAS:ADMP, OTCPK:MRPHF, NAS:JNP, NAS:CPIX » details
Traded in other countries:135.Germany,
SCYNEXIS Inc is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs.

SCYNEXIS Inc was incorporated in Delaware in November 4, 1999 as ScyRex, Inc. In June 2002, the Company changed its name to SCYNEXIS Inc. It is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs. The Company is developing its product candidate SCY-078, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, it has a clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases. It also provides contract research and development services in the field of animal health. The Company's competitors include pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies.

Ratios

vs
industry
vs
history
PB Ratio 1.48
SCYX's PB Ratio is ranked higher than
75% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. SCYX: 1.48 )
Ranked among companies with meaningful PB Ratio only.
SCYX' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.87 Max: 3.5
Current: 1.48
1.08
3.5
PS Ratio 184.63
SCYX's PS Ratio is ranked lower than
95% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. SCYX: 184.63 )
Ranked among companies with meaningful PS Ratio only.
SCYX' s PS Ratio Range Over the Past 10 Years
Min: 0.42  Med: 45.61 Max: 303.91
Current: 184.63
0.42
303.91
Current Ratio 15.96
SCYX's Current Ratio is ranked higher than
98% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. SCYX: 15.96 )
Ranked among companies with meaningful Current Ratio only.
SCYX' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 7.27 Max: 15.96
Current: 15.96
0.16
15.96
Quick Ratio 15.96
SCYX's Quick Ratio is ranked higher than
98% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. SCYX: 15.96 )
Ranked among companies with meaningful Quick Ratio only.
SCYX' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 7.27 Max: 15.96
Current: 15.96
0.16
15.96
Days Sales Outstanding 332.21
SCYX's Days Sales Outstanding is ranked lower than
96% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. SCYX: 332.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCYX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.57  Med: 65.68 Max: 1320.82
Current: 332.21
15.57
1320.82

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.56
SCYX's Price-to-Net-Cash is ranked higher than
95% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.69 vs. SCYX: 1.56 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SCYX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.53  Med: 2.18 Max: 3.26
Current: 1.56
1.53
3.26
Price-to-Net-Current-Asset-Value 1.54
SCYX's Price-to-Net-Current-Asset-Value is ranked higher than
93% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. SCYX: 1.54 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SCYX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.51  Med: 2.1 Max: 2.54
Current: 1.54
1.51
2.54
Price-to-Tangible-Book 1.51
SCYX's Price-to-Tangible-Book is ranked higher than
77% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. SCYX: 1.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SCYX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.48  Med: 2.06 Max: 2.54
Current: 1.51
1.48
2.54
Price-to-Median-PS-Value 4.07
SCYX's Price-to-Median-PS-Value is ranked lower than
93% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. SCYX: 4.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCYX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 4.69 Max: 5.91
Current: 4.07
0.29
5.91
Earnings Yield (Greenblatt) % -112.79
SCYX's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SCYX: -112.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCYX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -119.74  Med: 135.55 Max: 8156.7
Current: -112.79
-119.74
8156.7

More Statistics

Revenue (TTM) (Mil) $0.26
EPS (TTM) $ -1.61
Short Percentage of Float21.47%
52-Week Range $1.74 - 5.51
Shares Outstanding (Mil)24.61

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 0 0 1
EPS ($) -1.48 -1.58 -1.31
EPS without NRI ($) -1.48 -1.58 -1.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:SCYX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlights Jul 05 2016 

More From Other Websites
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Mar 23 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and... Mar 21 2017
SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
SCYX REMINDER: Rosen Law Firm Reminds SCYNEXIS, Inc. Investors of Important Deadline in Class Action... Mar 20 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of a Class Action... Mar 20 2017
SHAREHOLDER ALERT: Goldberg Law PC Announces the filing of a Class Action Lawsuit against SCYNEXIS,... Mar 17 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Mar 17 2017
IMPORTANT SCYNEXIS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a... Mar 17 2017
SCYNEXIS INC Financials Mar 17 2017
SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Mar 16 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Mar 15 2017
Pawar Law Group Announces Filing of a Securities Class Action Lawsuit Against SCYNEXIS, Inc. - SCYX Mar 15 2017
Robbins Arroyo LLP: SCYNEXIS, Inc. (SCYX) Misled Shareholders According to a Recently Filed Class... Mar 14 2017
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who... Mar 14 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Mar 14 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against SCYNEXIS,... Mar 14 2017
SCYX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a... Mar 14 2017
SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update Mar 13 2017
SCYNEXIS INC Files SEC form 10-K, Annual Report Mar 13 2017
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc.... Mar 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)